
    
      4.1 Study design The study will be a prospective multicentre randomized, examiner blinded
      controlled clinical trial of 24 months duration. Change in mucosal inflammation will be
      reported after 6 months while the true endpoint parameters i.e., peri-implant attachment will
      be reported after 1 and 2 years.

      4.2 Treatment allocation and blinding Patients will be allocated either to test (Labrida
      BioCleanÂ® or control (titanium curettes) treatment by computer-generated block randomization
      to ensure equal sample sizes. The examiners will be blinded to the treatment allocation.

      4.3 Study setting In total six centres will be included. Patient screening, inclusions and
      all clinical examinations will be performed by a board-certified specialist in
      periodontology, registered dental hygienist or specialist in prosthetics at each centre.
      Treatments will be performed by a dental hygienist or a board-certified specialist in
      periodontology.

      4.4 Patients 40 patients (20+20) diagnosed with mild to moderate peri-implantitis, defined as
      peri-implant bone loss 2 -4 mm, will be included by each clinician participating in the
      study.

      4.5 Recruitment of patients

      Patients referred to or seeking care in the included clinics will be screened for inclusion.
    
  